Skip to main content
. 2019 Aug 27;24(17):3110. doi: 10.3390/molecules24173110

Figure 4.

Figure 4

Kurarinone exerts cytostatic effects on cancer cells. (A) PC3 and TIG3 cells were incubated with the indicated doses of kurarinone for 48 h. Cell viability was determined by WST-8 assay. Results represent the mean ± S.D. (n = 3). (B) PC3 cells were incubated with the indicated doses of kurarinone for 48 h. Cells were labeled with 10 μM of BrdU for 1 h and analyzed by fluorescence-activated cell sorting. The average percentage of BrdU-positive cells is shown. Results represent the mean ± S.D. (n = 3). (C) PC3 cells were exposed to the indicated doses of kurarinone for 48 h. The percentage of dead cells was measured by trypan blue staining. Results were shown as the mean ± S.D. (n = 3). (D) PC3 cells were incubated with the indicated doses of TG or kurarinone for 6 h. Cell lysates were immunoblotted with the indicated antibodies. (E) PC3 and TIG3 cells were exposed to the indicated doses of kurarinone with or without 1 μM of GSK2656157 (GSK) for 48 h. Cell viability was determined by WST-8 assay as in (A). Results represent the mean ± S.D. (n = 3). Significant differences are indicated as ** p < 0.01. * p < 0.05. n.s.: not significant.